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ABSTRACT
In South American countries, the class A extended-spectrum b-lactamases (ESBLs) so far recognised
belong to the CTX-M, Pseudomonas Extended Resistance (PER), SHV and TEM families. ESBL rates in
South America are among the highest in the world, probably due to multiple factors. SHV- and TEM-
type ESBLs have been frequently encountered, but CTX-M is endemic and widely dominant. PER-type
ESBLs seem to be restricted to the southern ‘cone’ of South America. Community-acquired ESBLs are
starting to appear.
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The ﬁrst reports of extended-spectrum b-lactamase
(ESBL) enzymes came from Germany in 1985 [1,2],
describing the discovery of SHV variants, specif-
ically SHV-2. By 1986–1987, Klebsiella isolates with
transmissible resistance to cefotaxime and other
b-lactams had emerged also in France [3] and, soon
after that, there was an explosion of reports of
ESBLs throughout the world. South America was
not the exception, and it has been proposed that
ESBLs, including CTX-M types, were common in
South America as early as 1989 [4].
In general, the spread of infections due to ESBL
producers has been greater in countries with
lower economic resources. This is very clear when
comparing prevalence data from Sweden (3%)
with those from Greece, Turkey, Portugal (>25%)
[5,6] or South America (>30%) [7–9]. Several
reasons may account for this disparity: (i) poorer
social and economic conditions; (ii) crowded
hospitals, frequently with high patient ⁄
nurse ratios; (iii) self-prescription of antibiotics,
which are sold over the counter in most of South
America; and (iv) deﬁcient hospital hygiene,
resulting in high rates of colonisation and infec-
tion with Klebsiella spp. This last factor is very
important because Klebsiella spp. have a particular
ability to acquire plasmids determining ESBL
production.
Based on recent multi-continent surveys, Kleb-
siella isolates from Latin America have the highest
ESBL prevalence in the world (45.4–51.9%)
[10,11]. The prevalence among Escherichia coli
isolates, ranging from 8.5% to 18.1% in Latin
American countries, was also higher than in
developed countries [11]. However, ESBL rates
among Proteus mirabilis isolates differ widely in
different continents. They were lower in northern
South America while very frequent in South
America as in Argentina (33% to 40%) [8,10,24]
(6.2%) than in eastern and southern Europe
(21.3% and 20.5%, respectively) [11].
Differences among South American countries
are observed too, although analysis is compli-
cated, depending on the isolates selected for each
study. Klebsiella isolates from intensive care units
in Brazil, Colombia and Venezuela had ESBL rates
ranging from 30% to 60% [12–18], while 56.6% of
Klebsiella pneumoniae isolates from blood samples
in Brazil were ESBL producers [19]. Among
Escherichia coli blood isolates from Uruguay and
Chile, ESBLs were expressed in 4.5% and 12%,
respectively. In Colombia, our studies of isolates
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from multiple sources showed higher rates of
ESBLs—up to 16.7%—and revealed a few clonally
related producers [20]. The absence of clonality in
most cases suggests that improved infection con-
trol will not be an adequate control measure by
itself; better antibiotic use will also be required.
TEM-type ESBLs
Most TEM-derived ESBLs, derived from TEM-1,
an extremely common enzyme known since 1965
[21,22], are more active against ceftazidime than
cefotaxime or ceftriaxone. The ﬁrst report of a
TEM-type enzyme in South America was made by
Paterson et al. in 2003, when they discovered a
TEM-10 enzyme in bloodstream isolates of
K. pneumoniae from Argentina [23]. TEM-10 and
TEM-26 are among the most common TEM ESBLs
in the USA and many European countries [20],
and Jacoby and Mun˜oz-Price recently stated that
they are also frequent in South America. How-
ever, there are marked geographical differences.
In Colombia, TEM (and SHV) ESBLs are widely
prevalent among E. coli and actually seldom
found [21] in southern South America [24].
SHV-type ESBLs
SHV-type ESBLs are all derived from SHV-1 by
point mutations, with more than 90 ESBL variants
so far described (http://www.lahey.org/studies/).
This family of ESBLs currently predominates in
surveys of resistant isolates in South America
[21,25–27]. The ﬁrst reports of SHV-type enzymes
in South America came from Argentina and Chile
in 1988 and 1989, and concern SHV-2 and SHV-5
[21]. A K. pneumoniae isolate collected during a
preclinical study of cefotaxime in Buenos Aires,
and kept lyophilised since 1982, proved to be a
producer of an SHV-5 enzyme when retrospec-
tively tested, which proves that ESBLs were
circulating long before they were recognised in
South America, or elsewhere (J. M. Casellas,
Abstracts of the International Congress of
Chemotherapy, Birmingham, UK, 1999). Today,
SHV-5 and SHV-12 are among the most common
members of this family [28].
CTX-M-type ESBLs
In 1990, Bauernfeind et al., from Mu¨nchen Uni-
versity, reported an E. coli clinical isolate obtained
in East Germany that produced a non-SHV, non-
TEM ESBL that hydrolysed cefotaxime but had
only trace activity against ceftazidime. The en-
zyme was designated CTX-M-1, thus creating the
‘cefotaximase family’ (CTX-M family), which now
comprises more than 60 enzymes [22,29]. These
enzymes are increasingly more prevalent than the
classic TEM- and SHV-type ESBLs [30].
Although the description of the ﬁrst CTX-M
enzymes came from Europe, South America was
the ﬁrst continent where they became prevalent
[29]. It now appears that CTX-M enzymes had
been widely distributed in South America from
1989 [4]. In that year, non-typhoidal Salmonella
strains producing the CTX-M-2 enzyme began to
spread from neonatal units, initially in La Plata
and Buenos Aires, Argentina. From there, these
enzymes spread to neighbouring South American
countries, including Paraguay, Uruguay and Bra-
zil [31]. By 1994, CTX-M-2 was being reported in
Klebsiella isolates from Paraguay and E. coli and
P. mirabilis isolates from Argentina [4]. Other
bacteria known to harbour this enzyme in South
America include Shigella sonnei, Morganella mor-
ganii, Citrobacter freundii, Serratia marcescens, Ente-
robacter aerogenes, Vibrio cholerae and Aeromonas
hydrophyla [4,21]. By 2002, CTX-M-2 was the
enzyme present in c. 75% of ESBL-producing
Enterobacteriaceae in Buenos Aires, making it
clearly the predominant ESBL in the country
[29,32]. CTX-M-31 (a variant of CTX-M-2) has also
been reported from Argentina [8].
Other CTX-M enzymes, including CTX-M-8,
CTX-M-9 and CTX-M-16, have been discovered in
Enterobacteriaceae from Brazil since 1996 [33].
In Colombia, seven K. pneumoniae isolates, col-
lected in 2004 from three hospitals, were positive
for CTX-M-1-group enzymes, and CTX-M-12 was
identiﬁed in one isolate [33]. This was the ﬁrst
report of CTX-M-12 outside of Kenya, where the
enzyme was found in an outbreak among six
newborn babies in 2001 [34]. Peru and Bolivia
have reported CTX-M-2, CTX-M-14, CTX-M-15,
CTX-M-24 and, recently, a new CTX-M variant,
CTX-M-56 [30,35].
Pseudomonas Extended Resistance-type ESBLs
Pseudomonas Extended Resistance (PER) enzymes
represent a distinct A ESBL class, presently
restricted to South America, Asia and Europe
[6,36,37]. These enzymes share low sequence
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homology (25–27%) with TEM, SHV or CTX-M
enzymes [37]. PER-type ESBLs are among the
most efﬁcient b-lactamases against broad-spec-
trum cephalosporins [36,37]. Two PER enzymes
from very different geographical areas are
known at present. PER-1 was ﬁrst detected in
Pseudomonas aeruginosa, Salmonella spp. and Aci-
netobacter spp. from Turkey [37], and PER-2 was
ﬁrst detected in an isolate of Salmonella enterica
recovered by Casellas et al. in Buenos Aires
[38,39]. Later on, PER-2 was detected in several
Enterobacteriaceae, and even in Vibrio cholerae
[40].
Unlike PER-1, PER-2 has never been reported
in P. aeruginosa. It seems to be restricted to
Argentina and bordering countries such as Chile,
Paraguay and Uruguay [4]. In Argentina, PER-2 is
the second most prevalent ESBL after CTX-M-2
[41].
Other ESBLs
Two novel non-TEM non-SHV ESBLs have
been reported from South America: the ceftazi-
dime-hydrolysing Guiana Extended-Spectrum-1,
isolated from K. pneumoniae from an infant
previously hospitalised in French Guiana [42],
and Brazil Extended-Spectrum-1 (BES), from an
S. marcescens isolate collected in Rio de Janeiro in
1997 [42]. BES-1 exhibits greater catalytic activity
against ceftazidime and aztreonam than do
CTX-M enzymes and was the ﬁrst ESBL shown
to exhibit selective resistance to tazobactam
[27,28].
A NEW CHALLENGE: ESBLs IN
COMMUNITY-ACQUIRED INFECTIONS
Most community-acquired ESBL producers in
Latin America and in other developing countries
are Salmonella and Shigella spp. isolates [43,44].
However, several reports of community-acquired
E. coli and K. pneumoniae infection not related to
nursing homes or hospitals have been published
in the past several years. These reports come from
Spain, France, Israel, the UK and Canada, and
mostly concern strains with the CTX-M-class
enzymes. In the last year, at least two or three
community-acquired infections due to ESBL
producers have been detected in Argentina
(J. M. Casellas, unpublished data). A recent report
from Brazil showed a 1.48% prevalence of ESBLs
among enterobacterial isolates collected from
urine samples in ambulatory patients between
2000 and 2002. TEM-type enzymes were identi-
ﬁed in 95.4% of the isolates, with SHV types
being found in most of the remainder, although
seven strains produced CTX-M-type enzymes.
Pulsed-ﬁeld gel electrophoresis showed several
identical genotypes, indicating a common source
of acquisition [45]. Surveys of over 3000 healthy
children from low-resource settings in Bolivia and
Peru revealed an increase in faecal carriage of
ESBL-producing E. coli from 0.1% in 2002 to 1.7%
in 2005 [30]. Of 50 ESBL-producing isolates
collected in 2005, 44 harboured a CTX-M-type
enzyme and six had SHV-type enzymes.
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